Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropivacaine Celiac Plexus Block in HPB Surgery
NCT06214533Not yet recruiting
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Mar 2024
- Primary completion
- Aug 2025
- Modality
- Orthosteric Ligands
01
Overview
Randomised, double-blind trial of ropivacaine in pancreatic ductal adenocarcinoma (PDAC) and liver cancer (2 arms), sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Primary endpoint: Postoperative opioid use at 24 hours. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
ropivacaine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)liver cancer
Beyond the preview
Go deeper on NCT06214533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06214533.